Literature DB >> 24841543

Radioactive self-expanding stents give superior palliation in patients with unresectable cancer of the esophagus but should be used with caution if they have had prior radiotherapy.

Ning Liu1, Shuguang Liu2, Cheng Xiang3, Ning Cong1, Bing Wang4, Bo Zhou5, Benwu Zhang6, Yuliang Li7, Yongzheng Wang7, Shuanghu Yuan8.   

Abstract

BACKGROUND: Self-expandable stents loaded with 125I (iodine 125) seeds may combine the advantages of the immediate relief of esophageal dysphagia with stent placement and radiation therapy with brachytherapy. We compared the self-expanding irradiation stent with a conventional self-expandable covered stent in patients with malignant dysphagia due to recurrent esophageal cancer.
METHODS: The patients with recurrent esophageal cancer suffering from dysphagia (≥grade 2) were enrolled and placed with a stent loaded with 125I seeds (irradiation stent group) or a conventional covered stent (traditional stent group). After stent placement, the outcomes were compared in terms of relief of dysphagia, survival time, and complications related to the procedure.
RESULTS: Primary stent placements were successful in 29 of 31 (93.5%) cases in the irradiation stent group and 30 of 32 (93.8%) cases in the traditional stent group. The dysphagia grades significantly improved in both groups within the first month after stent placement but were better in the irradiation stent group than in the traditional stent group after 3 months (p=0 .04). The median survival was 4 months in the radiation stent group and 3 months in the traditional stent group (p=0.06). Bleeding occurred in 35.5% versus 21.9% patients in the irradiation stent group versus the traditional stent group during follow-up (p=0.232).
CONCLUSIONS: This study indicated that the radiation stent had a potential benefit of a longer dysphagia relief period. However, no significant survival benefits were observed in the radiation stent group and the high incidence rate of massive hemorrhages further limited its application in patients with malignant dysphagia due to recurrent esophageal cancer.
Copyright © 2014 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24841543     DOI: 10.1016/j.athoracsur.2014.04.012

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  The clinical research of the endoscopic sequential treatment for patients with intermediate-advanced esophageal cancer: a randomized clinical trial.

Authors:  Liming Wen; Honglin Quan; Linyan Li; Chun Huang; Xiaohui Chen; Yaling Yang; Liming Wang; Xiguo He; Xudong Zhang
Journal:  Med Oncol       Date:  2014-11-08       Impact factor: 3.064

2.  History of the Use of Esophageal Stent in Management of Dysphagia and Its Improvement Over the Years.

Authors:  Kulwinder S Dua
Journal:  Dysphagia       Date:  2017-01-18       Impact factor: 3.438

3.  Dosimetric Evaluation and Clinical Application of Radioactive Iodine-125 Brachytherapy Stent in the Treatment of Malignant Esophageal Obstruction.

Authors:  Zhe Ji; Qianqian Yuan; Lei Lin; Chao Xing; Xusheng Zhang; Sen Yang; Yuliang Jiang; Haitao Sun; Kaixian Zhang; Junjie Wang
Journal:  Front Oncol       Date:  2022-03-24       Impact factor: 6.244

4.  The Mechanism of Computed Tomography-Guided 125I Particle in Treating Lung Cancer.

Authors:  Jianzhong Cheng; Shaozeng Ma; Guanghua Yang; Lisen Wang; Wei Hou
Journal:  Med Sci Monit       Date:  2017-01-17

Review 5.  Futuristic Developments and Applications in Endoluminal Stenting.

Authors:  Joel Ferreira-Silva; Renato Medas; Mohit Girotra; Monique Barakat; James H Tabibian; Eduardo Rodrigues-Pinto
Journal:  Gastroenterol Res Pract       Date:  2022-01-11       Impact factor: 2.260

6.  I-125 seed-loaded versus normal stent insertion for obstructive esophageal cancer: a meta-analysis.

Authors:  Chun-Lei Zhao; Bing Gu; Xiao-Bing Huo; Feng-Fei Xia
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2021-03-08       Impact factor: 1.195

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.